Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
Argenx Se (ARGX) Stock Price & Analysis
394 Followers
ARGX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$327.73 - $550.76
Previous Close$366.2
Volume194.82K
Average Volume (3M)304.88K
Market Cap
$21.20B
Enterprise Value$19.53B
Total Cash (Recent Filing)$2.05B
Total Debt (Recent Filing)$20.00M
Price to Earnings (P/E)-70.8
Beta0.47
Next Earnings
May 09, 2024EPS Estimate
-$0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.17
Shares Outstanding59,194,488
10 Day Avg. Volume183,384
30 Day Avg. Volume304,875
Standard Deviation0.12
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.52
Price to Sales (P/S)17.68
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue91.63
Enterprise Value/Gross Profit17.62
Enterprise Value/Ebitda-42.83
Forecast
1Y Price Target
$469.54Price Target Upside30.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Argenx Se News
PremiumCompany Announcements
Argenx’s VYVGART Shows Promising CIDP Treatment Results
PremiumCompany Announcements
Argenx Schedules Annual Shareholders’ Meeting 2024
PremiumCompany Announcements
Argenx Advances Promising Sjogren’s TreatmentBulls Say, Bears Say
Bulls Say
Competitive PositionWith the failure of a competitor's Phase 3 trial in generalized Myasthenia Gravis (gMG), this has positive readthrough to ARGX's Vyvgart, which is already approved for gMG and provided a strong benefit.
Drug Development ProgressARGX announced a 'GO' decision to advance efgartigimod into Phase 3 development in Sjogren's syndrome following encouraging topline results from the Phase 2 RHO trial.
Market OpportunityThe market opportunity for Sjögren's Syndrome is significant, with an estimated 330,000 patients in the US alone, and analysts estimate around $2 billion in peak US sales for Vyvgart, reflecting a substantial commercial potential.
Bears Say
Clinical Trial ResultsVyvgart Hytrulo in ITP missed on primary and secondary endpoints.
Competitive LandscapeCompeting candidate's clinical significance did not meet the company’s expectations in gMG.
Regulatory RisksUncertainty regarding the approval of IV efgartigimod for ITP treatment in Japan arises from recently disclosed negative results from the Phase 3 ADVANCE-SC trial.
---
Ownership Overview
0.00%
Insiders
23.34% Mutual Funds
1.87% Other Institutional Investors
74.79% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $327.73 and its highest was $550.76 in the past 12 months.
What is Argenx Se’s market cap?
Currently, no data Available
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Feb 29, 2024. The company reported -$1.68 earnings per share for the quarter, missing the consensus estimate of -$1.321 by -$0.359.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is -$0.73.
How many shares outstanding does Argenx Se have?
Argenx Se has 59,431,080 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of -$1.68 in its last earnings report, missing expectations of -$1.321. Following the earnings report the stock price went down -4.448%.
Which hedge fund is a major shareholder of Argenx Se?
Among the largest hedge funds holding Argenx Se’s share is Baker Bros Advisors LP. It holds Argenx Se’s shares valued at 58M.
---
Argenx Se Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$469.54 (30.41% Upside)
$469.54 (30.41% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 113.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 9.9%
Last 30 Days ▼ 9.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.62%
12-Months-Change
Fundamentals
Return on Equity
-8.55%
Trailing 12-Months
Asset Growth
44.93%
Trailing 12-Months
Company Description
Argenx Se
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.
---
ARGX Company Deck
---
ARGX Earnings Call
Q4 2024
0:00 / 0:00
---
ARGX Stock 12 Months Forecast
Average Price Target
$469.54
▲(30.41% Upside)
Technical Analysis
Best Analysts Covering ARGX
1 Year
1 Year Success Rate
13/16 ratings generated profit
1 Year Average Return
+15.65%
reiterated a buy rating 12 months ago
Copying Danielle Brill's trades and holding each position for 1 Year would result in 81.25% of your transactions generating a profit, with an average return of +15.65% per trade.
---